Singapore markets close in 2 hours 1 minute

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
13.45-2.69 (-16.69%)
At close: 04:00PM EDT
13.50 +0.05 (+0.33%)
After hours: 06:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close16.15
Open15.44
Bid13.42 x 200
Ask13.48 x 200
Day's range13.39 - 15.44
52-week range4.80 - 17.03
Volume1,102,077
Avg. volume853,837
Market cap702.233M
Beta (5Y monthly)1.51
PE ratio (TTM)N/A
EPS (TTM)-3.42
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.50
  • Business Wire

    CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant

    BRISBANE, Calif., May 29, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.’s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent).

  • Business Wire

    CareDx to Participate in Upcoming Investor Conferences

    BRISBANE, Calif., May 29, 2024--CareDx, Inc. (Nasdaq: CDNA), The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.

  • Business Wire

    Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

    BRISBANE, Calif., May 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.